Edgewise Therapeutics, Inc. · NASDAQ:EWTX
Edgewise Therapeutics — 2023 HCMS Scientific Sessions
9 slides from Edgewise Therapeutics's conference presentation, 2023
Slide 1: Targeting the Mechanism of Hypertrophic Cardiomyopathy
Targeting the Mechanism of Hypertrophic Cardiomyopathy Marc J. Semigran MD Chief Development Officer Edgewise Therapeutics 2023 HCMS Scientific Sessions #HCMS2023
Slide 2: Disclosures
Disclosures • Dr. Semigran is a full-time employee of Edgewise Therapeutics 2023 HCMS Scientific Sessions #HCMS2023 2
Slide 3: Disclaimer
Disclaimer This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”). All statements other than statements of historical facts contained in this presentation, including statements regarding our
Slide 4: Advancing EDG-7500, a First-In-Class Sarcomere Modulator for Hypertrophic Cardiomyopathy (HCM)
Advancing EDG-7500, a First-In-Class Sarcomere Modulator for Hypertrophic Cardiomyopathy (HCM) • Edgewise Therapeutics' robust discovery platform is yielding novel compounds targeting important unmet needs of patients suffering from inherited disorders of cardiac and skeletal muscle. • EDG-7500 is f
Slide 5: LVOT Obstruction in oHCM Patients Results from Abnormalities in Early Systolic LV Blood Flow
LVOT Obstruction in oHCM Patients Results from Abnormalities in Early Systolic LV Blood Flow & Mitral Leaflet Structure Normal Flow in Control Patient Systolic Anterior Motion in HCM Orderly clockwise Vector forces push ...resulting in blood flow vortex mitral leaflet outflow anteriorly... obstructi
Slide 6: Systolic Function: EDG-7500 Reduces the Rate of Pressure Development during Isovolumic Contraction
Systolic Function: EDG-7500 Reduces the Rate of Pressure Development during Isovolumic Contraction and Prolongs Pre Ejection Period; Stroke Volume is Preserved ✱✱ 10 2,100 PRE ✱ EDG-7500 (0.3 mg/kg) Pre Ejection Period (% cycle) STROKE VOLUME 1,800 dP/dtmax (mmHg/s) 8 LVP (mmHg) 1,500 6 -8% +9% 1,20
Slide 7: Diastolic Function: EDG-7500 Increases Left Ventricular Compliance
Diastolic Function: EDG-7500 Increases Left Ventricular Compliance 25 ns 12 PRE ✱✱ EDG-7500 End Diastolic Pressure (mmHg) End Diastolc Volume (RVU) 20 8 LVP (mmHg) 15 +7% 4 -10% 10 0 LVV (RVU) PRE POST PRE POST 0.3 mg/kg 0.3 mg/kg Healthy Dogs (n=4). Measurements made after iv EDG-7500 administratio
Slide 8: EDG-7500 Relieves LVOT Gradient Without Changing % Fractional Shortening in Cats with Genetic oHCM
EDG-7500 Relieves LVOT Gradient Without Changing % Fractional Shortening in Cats with Genetic oHCM EDG-7500 Driven LVFS Maintained with Oral LVOT Gradient Relief EDG-7500 Treatment ✱ 80 20 ns 60 15 PGLVOT (mmHg) LV FS (%) -2% 10 Clinically significant 40 pressure gradient in cats -66% 20 5 0 0 CTRL
Slide 9: Summary
Summary • Knowledge of muscle biology and the pathophysiologic mechanisms of HCM has informed design of a small molecule that directly targets both early-systolic and diastolic myocardial function with modest effects on overall systolic performance as measured by ejection-phase indices. • The myocar
Edgewise Therapeutics — 2023 HCMS Scientific Sessions on 6ix